Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Have you utilized JAK inhibitors in patients on dialysis?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
How do you approach managing nausea and GI side effects when initiating methotrexate?
